17,261 trials
Pneumococcal Infections
Primary: Percentage of Participants With an Adverse Event — 75.1; 68.3; 65.7 Percentage of Participants
ALS (Amyotrophic Lateral Sclerosis)
Primary: Change in Revised ALS Functional Rating Scale (ALSFRS-R) — 0.44 points per month — p=0.99
Schizophrenia
Primary: Social Affiliation Measured by Social Affiliative Role Play — 4.026; 4.111; 4.079; 4.194 units on a scale — p=0.758
Mucopolysaccharidosis (MPS)
Primary: Number of Treatment Emergent Serious Adverse Events (SAE) — 5; 3; 2 events
Breast Cancer
Primary: Number of Participants Who Experienced Toxicity to the Vaccine — 0; 0 Participants
HIV-1
Primary: Percentage of Participants With Clonal Expansion of Cells With a Predominant OZ1 Insertion Site — 0 Percentage of participants
Non-small Cell Lung Cancer
Primary: 2-year Disease-free Survival — 88 Participants
PTSD
Primary: Change in Amygdala Activation- Oxy Minus Placebo — -0.01; -0.02; 0.05; 0.21 percentage of BOLD signal change
Acne Vulgaris
Primary: Change in Total Acne Lesion Counts — -26.0; -25.2; -29.4; -33.1 Lesions
Hodgkin Disease
Primary: Objective Response Rate (ORR) Based on IRRC Assessments in Cohorts A, B, and C — 65.1; 67.5; 73.0 Percentage of Particpants
Brain Tumors With Ill-defined Margins
Primary: Extent of Resection — 97.1 percentage of tumor resected
Seborrheic Keratosis (SK)
Primary: Mean Change in Physician Lesion Assessment Scale — -0.47; -0.88; -1.12; -0.15 Change in Score on a scale
Castration Levels of Testosterone · Castration-Resistant Prostate Carcinoma · Metastatic Prostate Carcinoma
Primary: Quantification of T-cell Responses to Prostatic Acid Phosphatase Granulocyte-macrophage Colony-stimulating Factor (PAP-GM-CSF), Assessed by Quantification of Interferon…
Cholesterol Ester Storage Disease(CESD) · Lysosomal Acid Lipase Deficiency · LAL-Deficiency
Primary: Number Of Participants Reporting TEAEs And Infusion-Related Reactions (IRRs) — 1; 3; 3; 0 participants
Cancer · Giant Cell Tumors · Giant Cell Tumor of Bone
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 260; 231; 12; 98 Participants